ClinicalTrials.gg
RecruitingNCT06686394Updated Nov 16, 2026

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

A Phase 1/2 interventional study of Patritumab deruxtecan and Trastuzumab in Breast Neoplasms and Breast Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 18 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Oct 21, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
181
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Planned enrollment
6th of 12
181 · median 167
Started
2025
with 2 others
Phase 1/2
4 of 12
3 open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Merck Sharp & Dohme LLC

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 1/2, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment
Read the detailed description

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

03

Conditions studied

  • Breast Neoplasms
  • Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has confirmed + locally advanced unresectable breast cancer or breast cancer
  • (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable
  • (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current
  • Has corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active and infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any -targeted tyrosine kinase inhibitors in the locally advanced or setting

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
181 participants (estimated)

Study arms

  • Experimental
    Part 1: Patritumab deruxtecan plus trastuzumab

    Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

    Biological: Patritumab deruxtecan · Biological: Trastuzumab · Biological: Trastuzumab Biosimilar

  • Experimental
    Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

    Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

    Biological: Patritumab deruxtecan · Biological: Trastuzumab · Biological: Trastuzumab Biosimilar · Biological: Pertuzumab

  • Experimental
    Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

    Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

    Biological: Patritumab deruxtecan · Biological: Trastuzumab · Biological: Trastuzumab Biosimilar · Biological: Tucatinib

  • Experimental
    Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

    Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

    Biological: Patritumab deruxtecan · Biological: Trastuzumab · Biological: Trastuzumab Biosimilar · Biological: Pertuzumab

Interventions

  • Patritumab deruxtecan administered via IV infusion

    Also known as: MK-1022, HER3-DXd, U3-1402

  • BiologicalTrastuzumab

    Trastuzumab administered via IV infusion

    Also known as: Herceptin®

  • Trastuzumab biosimilar administered via IV infusion

    Also known as: Trazimera®, Ogivri®, Herzuma®, Ontruzant®, Kanjinti®, Hercessi®

  • BiologicalPertuzumab

    Pertuzumab administered via IV infusion

  • BiologicalTucatinib

    Tucatinib administered as oral tablets

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)

    DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

    Time frame: Up to 21 days

  2. Part 1: Number of Participants with One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

    Time frame: Up to approximately 36 months

  3. Part 1: Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 12 months

  4. Part 2: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)

    Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

    Time frame: At designated time points (up to ~13 months)

  2. Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

    Time frame: At designated time points (up to ~13 months)

  3. Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC

    Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

    Time frame: At designated time points (up to ~13 months)

  4. Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)

    Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

    Time frame: At designated time points (up to ~13 months)

  5. Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA

    Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

    Time frame: At designated time points (up to ~13 months)

  6. Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA

    Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

    Time frame: At designated time points (up to ~13 months)

  7. Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload

    Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

    Time frame: At designated time points (up to ~13 months)

  8. Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload

    Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

    Time frame: At designated time points (up to ~13 months)

  9. Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload

    Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

    Time frame: At designated time points (up to ~13 months)

  10. Part 2: Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 36 months

  11. Part 2: Progression Free Survival (PFS)

    PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 36 months

  12. Part 2: Number of Participants with One or More AEs

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

    Time frame: Up to approximately 36 months

  13. Part 2: Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

    Time frame: Up to approximately 12 months

07

Study locations

18 of 18 sites recruiting
  • University of Colorado Anschutz Medical Campus ( Site 0057)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact720-848-1030
  • Dana-Farber Cancer Institute ( Site 0050)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Study Coordinator · Contact877-338-7425
  • Rutgers Cancer Institute of New Jersey ( Site 0052)
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Study Coordinator · Contact732-235-2465
  • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
    Greenville, South Carolina 29605, United States
    Recruiting
    • Study Coordinator · Contact864-455-3600
  • Inova Schar Cancer Institute ( Site 0051)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact571-472-4724
  • Kingston General Hospital ( Site 0061)
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Study Coordinator · Contact6135336541
  • Princess Margaret Cancer Centre ( Site 0001)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact416-946-4501
  • Centre Hospitalier de l'Université de Montréal ( Site 0004)
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
    • Study Coordinator · Contact(514)890-8000 x20737
  • Jewish General Hospital ( Site 0003)
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
    • Study Coordinator · Contact514-340-8222
  • Rambam Health Care Campus ( Site 0011)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact04-7776234
  • Rabin Medical Center ( Site 0012)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+972-505533121
  • Sheba Medical Center ( Site 0010)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact03-5304498
  • Nagoya City University Hospital ( Site 0020)
    Nagoya, Aichi-ken 467-8602, Japan
    Recruiting
    • Study Coordinator · Contact+81-52-851-5511
  • Seoul National University Hospital ( Site 0030)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-2072-0850
  • Asan Medical Center ( Site 0031)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82-2-1688-7575
  • University College London Hospital ( Site 0041)
    London, Camden NW1 2PG, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442034472930
  • The Beatson West of Scotland Cancer Centre ( Site 0043)
    Glasgow, Glasgow City G12 0YN, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441413017000
  • St Bartholomew s Hospital ( Site 0040)
    London, London, City of EC1A 7BE, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442073777000
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2032, 89 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 89 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Apr 2030 → Aug 2032 and completion Apr 2030 → Aug 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartActual
Feb 26, 2025
Primary completionEst.
Aug 2, 2032was Apr 2030
CompletionEst.
Aug 2, 2032was Apr 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 18, 2030→Aug 2, 2032
Oct 21, 2026
Study completion
Apr 18, 2030→Aug 2, 2032
Oct 21, 2026
Enrollment
81→181
Oct 6, 2026
Eligibility
3 inclusion criteria edited, 1 added; 3 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedPart 1 Arm 1:
  • EditedPart 1 Arm 2:
  • EditedPart 1 Arm 3:
  • AddedPart 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion criteria
  • EditedHistoryHas any history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids/ pneumonitis irrespective of steroid use or has current pneumonitis/interstitial lung diseaseILD or suspected ILD
  • EditedPart 1: Evidence of spinal cord compression or brain metastases
  • AddedPart 2: Evidence of spinal cord compression or brain/CNS metastases.
  • EditedPart1: Arm 3 ONLY
Oct 6, 2026
Interventions
Arm changed Patritumab deruxtecan plus trastuzumab→Part 1: Patritumab deruxtecan plus trastuzumab; Patritumab deruxtecan plus trastuzumab and tucatinib→Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib; Patritumab deruxtecan plus pertuzumab and trastuzumab→Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab. Arms added: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Oct 6, 2026
Primary outcomes
3 edited, 1 added
What changed in the outcomes
  • EditedPart 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days
  • EditedPart 1: Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 13 months → Up to approximately 36 months
  • EditedPart 1: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 12 months
  • AddedPart 2: Objective Response Rate (ORR)Time frame: Up to approximately 36 months
Oct 6, 2026
Secondary outcomes
9 edited, 4 added
What changed in the outcomes
  • EditedPart 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)Time frame: At designated time points (up to ~13 months)
  • EditedPart 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADCTime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADCTime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)Time frame: At designated time points (up to ~13 months)
  • EditedPart 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADATime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADATime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
  • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
  • AddedPart 2: Duration of Response (DOR)Time frame: Up to approximately 36 months
  • AddedPart 2: Progression Free Survival (PFS)Time frame: Up to approximately 36 months
  • AddedPart 2: Number of Participants with One or More AEsTime frame: Up to approximately 36 months
  • AddedPart 2: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 12 months
Oct 6, 2026
Show all 3 updates
  1. Nov 16, 2026
    Minor edits only
    + 3 other changes: verification date, site details and references
  2. Oct 21, 2026
    Primary completion Apr 18, 2030→Aug 2, 2032
    Study completion Apr 18, 2030→Aug 2, 2032
  3. Oct 6, 2026
    Enrollment 81→181
    Eligibility 3 inclusion criteria edited, 1 added; 3 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedPart 1 Arm 1:
    • EditedPart 1 Arm 2:
    • EditedPart 1 Arm 3:
    • AddedPart 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
    Exclusion criteria
    • EditedHistoryHas any history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids/ pneumonitis irrespective of steroid use or has current pneumonitis/interstitial lung diseaseILD or suspected ILD
    • EditedPart 1: Evidence of spinal cord compression or brain metastases
    • AddedPart 2: Evidence of spinal cord compression or brain/CNS metastases.
    • EditedPart1: Arm 3 ONLY
    Primary outcomes 3 edited, 1 added
    What changed in the outcomes
    • EditedPart 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days
    • EditedPart 1: Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 13 months → Up to approximately 36 months
    • EditedPart 1: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 12 months
    • AddedPart 2: Objective Response Rate (ORR)Time frame: Up to approximately 36 months
    Secondary outcomes 9 edited, 4 added
    What changed in the outcomes
    • EditedPart 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)Time frame: At designated time points (up to ~13 months)
    • EditedPart 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADCTime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADCTime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)Time frame: At designated time points (up to ~13 months)
    • EditedPart 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADATime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADATime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
    • EditedPart 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free PayloadTime frame: At designated time points (up to ~13 months)
    • AddedPart 2: Duration of Response (DOR)Time frame: Up to approximately 36 months
    • AddedPart 2: Progression Free Survival (PFS)Time frame: Up to approximately 36 months
    • AddedPart 2: Number of Participants with One or More AEsTime frame: Up to approximately 36 months
    • AddedPart 2: Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 12 months
    Interventions Arm changed Patritumab deruxtecan plus trastuzumab→Part 1: Patritumab deruxtecan plus trastuzumab; Patritumab deruxtecan plus trastuzumab and tucatinib→Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib; Patritumab deruxtecan plus pertuzumab and trastuzumab→Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab. Arms added: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06686394
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Feb 26, 2025
Primary completion
Aug 2, 2032 (estimated)
Completion
Aug 2, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion